The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease.
Open accessAbstract
A ntiplatelet therapy, particularly with aspirin, has become the focus of much research in the treatment and prevention of cardiovascular disease.In this paper, we review the evidence of efficacy; first, for patients who have a history of myocardial infarction (M1), stroke, tran- sient cerebral ischemia (TCI), or unstable angina; second, for those actually undergoing acute myo- cardial infarction (AMI); and, finally, for appar- ently healthy individuals.Mechanism of Action of Aspinin Aspirin permanently inhibits cyclooxygenasedependent platelet aggregation.1-8Even low dose aspirin (e.g., 80 mg/day) will, within a few days, inhibit platelet cyclooxygenase so completely that little further effect on this mechanism of platelet aggregation would be expected at higher daily doses of the drug,3'6'8 although, if antiplatelet therapy is to be started during an acute vascular event, such as MI, then a somewhat higher loading dose (at least 160 mg) might be preferred to ensure a rapid antithrombotic effect.During the past 20 years, there have been reports from observational epidemiologic studies of aspirin as well as a number of randomized trials.Taken as a whole, the case-control and cohort studies suggest that aspirin may reduce the incidence of cardiovas- cular disease by about 20%,9-12 which, if true, would be clinically worthwhile and would have an important impact on public health.Unfortunately, however, the amount of uncontrolled confounding inherent in such observational studies could be about as great as the postulated benefit.13In gen- eral, reliable assessment of such modest benefits can be derived only from large randomized trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blood pressure, stroke, and coronary heart disease
Collins, R., Peto, R., MacMahon, S., Godwin, J., Qizilbash, N., Collins, R., MacMahon, S., Hebert, P., Eberlein, K. A., Taylor, J. O., et al. (1990) · The Lancet · doi:10.1016/0140-6736(90)90944-z · Cited by 4,491
Self-citationPeto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
Self-citationLewis, H. D., Davis, J. W., Archibald, D. G., Steinke, W. E., Smitherman, T. C., Doherty, J. E., Schnaper, H. W., LeWinter, M. M., Linares, E., Pouget, J. M., et al. (1983) · New England Journal of Medicine · doi:10.1056/nejm198308183090703 · Cited by 1,709
Randomised trial of prophylactic daily aspirin in British male doctors
Peto, R., Gray, R., Collins, R., Wheatley, K., Hennekens, C., Jamrozik, K., Warlow, C., Hafner, B., Thompson, E., Norton, S., et al. (1988) · BMJ · doi:10.1136/bmj.296.6618.313 · Cited by 1,166
Self-citationAspirin, Sulfinpyrazone, or Both in Unstable Angina: Results of a Canadian Multicenter Trial
Cairns, J. A., Gent, M., Singer, J., Finnie, K. J., Froggatt, G. M., Holder, D. A., Jablonsky, G., Kostuk, W. J., Melendez, L. J., Myers, M. G., et al. (1985) · New England Journal of Medicine · doi:10.1056/nejm198511283132201 · Cited by 1,120
Acetylation of prostaglandin synthase by aspirin.
Roth, G. J., Stanford, N., & Majerus, P. W. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.8.3073 · Cited by 1,009
Pharmacologic Aspects of Cigarette Smoking and Nicotine Addiction
Oates, J. A., Wood, A. J. J., & Benowitz, N. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198811173192005 · Cited by 971
Inhibition of platelet prostaglandin synthetase by oral aspirin.
Burch, J. W., Stanford, N., & Majerus, P. W. (1978) · Journal of Clinical Investigation · doi:10.1172/jci108941 · Cited by 558
Elwood, P. C., Cochrane, A., Burr, M. L., Sweetnam, P. M., Williams, G., Welsby, E., Hughes, S. J., & Renton, R. (1974) · BMJ · doi:10.1136/bmj.1.5905.436 · Cited by 519
(1980) · Circulation · doi:10.1161/01.cir.62.3.449 · Cited by 468
IMPAIRED PLATELET/CONNECTIVE-TISSUE REACTION IN MAN AFTER ASPIRIN INGESTION
Weiss, H., & Aledort, L. (1967) · The Lancet · doi:10.1016/s0140-6736(67)91658-3 · Cited by 379
ASPIRIN AND SECONDARY MORTALITY AFTER MYOCARDIAL INFARCTION
Elwood, P. C., & Sweetnam, P. M. (1979) · The Lancet · doi:10.1016/s0140-6736(79)92808-3 · Cited by 360
SOME VIRUS ISOLATIONS FROM COMMON COLDS
Hitchcock, G., & Tyrrell, D. A. J. (1960) · The Lancet · doi:10.1016/s0140-6736(60)90167-7 · Cited by 357
Cigarette Smoking and Risk of Stroke in Middle-Aged Women
Colditz, G. A., Bonita, R., Stampfer, M. J., Willett, W. C., Rosner, B., Speizer, F. E., & Hennekens, C. H. (1988) · New England Journal of Medicine · doi:10.1056/nejm198804143181501 · Cited by 299
Self-citationDIFFERENTIAL INHIBITION OF PROSTACYCLIN PRODUCTION AND PLATELET AGGREGATION BY ASPIRIN
Masotti, G., Poggesi, L., Galanti, G., Abbate, R., & Neri Serneri, G. G. (1979) · The Lancet · doi:10.1016/s0140-6736(79)92334-1 · Cited by 284
Klimt, C. R., Knatterud, G. L., Stamler, J., & Meier, P. (1986) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(86)80489-2 · Cited by 254
High-dose acetylsalicylic acid after cerebral infarction. A Swedish Cooperative Study.
(1987) · Stroke · doi:10.1161/01.str.18.2.325 · Cited by 182
ASPIRIN: A PARADOXICAL EFFECT ON BLEEDING-TIME
O’Grady, J., & Moncada, S. (1978) · The Lancet · doi:10.1016/s0140-6736(78)92661-2 · Cited by 156
The 2 × 2 factorial design: Its application to a randomized trial of aspirin and U.S. physicians
Stampfer, M. J., Buring, J. E., Willett, W. C., ROSNER, B. A., Eberlein, K. A., & Hennekens, C. H. (1985) · Statistics in Medicine · doi:10.1002/sim.4780040202 · Cited by 120
Self-citationAn Overview of the British and American Aspirin Studies
Hennekens, C. H., Peto, R., Hutchison, G. B., & Doll, R. (1988) · New England Journal of Medicine · doi:10.1056/nejm198804073181412 · Cited by 115
Self-citationTHE COMMUNITY-BASED RANDOMIZED TRIALS OF PHARMACOLOGIC TREATMENT OF MILD-TO-MODERATE HYPERTENSION
Hebert, P. R., Fiebach, N. H., Eberlein, K. A., Taylor, J. O., & Hennekens, C. H. (1988) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a114833 · Cited by 73
Self-citationRegular aspirin use and myocardial infarction.
Jick, H., & Miettinen, O. S. (1976) · BMJ · doi:10.1136/bmj.1.6017.1057 · Cited by 58
Stampfer, M. J., Jakubowski, J. A., Deykin, D., Schafer, A. I., Willett, W. C., & Hennekens, C. H. (1986) · The American Journal of Medicine · doi:10.1016/0002-9343(86)90289-5 · Cited by 42
Self-citation
Cited by
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Blood pressure, stroke, and coronary heart disease
Collins, R., Peto, R., MacMahon, S., Godwin, J., Qizilbash, N., Collins, R., MacMahon, S., Hebert, P., Eberlein, K. A., Taylor, J. O., et al. (1990) · The Lancet · doi:10.1016/0140-6736(90)90944-z · Cited by 4,491
Self-citationThe Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes
Epstein, F. H., Fuster, V., Badimon, L., Badimon, J. J., & Chesebro, J. H. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201303260506 · Cited by 3,725
Antiplatelet Trialists' Collaboration (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 3,126
Aspirin as an Antiplatelet Drug
Wood, A. J. J., & Patrono, C. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405053301808 · Cited by 955
Metadata
- Authors
- Hennekens, C. H., Buring, J. E., Sandercock, P., Collins, R., & Peto, R.
- Venue
- Circulation
- Published
- 1989-10
- Volume
- 80
- Issue
- 4
- Pages
- 749-756
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2052000438
- Cited by
- 253
- References
- 24
- FWCI
- 19.26
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.